The COPA vesicle protein and pathogenesis of spinal muscular atrophy

COPA囊泡蛋白与脊髓性肌萎缩症发病机制

基本信息

项目摘要

ABSTRACT The pathogenesis of motor neuron and muscle dysfunction in spinal muscular atrophy (SMA), a leading genetic cause of infant mortality, is still unresolved. SMA results from low levels of the Survival Motor Neuron SMN protein. The rationale underlying these experiments is our discovery that the SMN protein binds to and moves in neurons together with the CopA protein, the largest constituent of the heptameric COPI coatomer complex. The objective of this proposal is to determine the molecular mechanisms by which reduced SMN interaction with COPI complex and loss of COPI activities leads to neurodegeneration. Golgi-derived COPI vesicles are necessary for post-translational processing and transport of proteins and other cargoes between Golgi apparatus and endoplasmic reticulum and secretory pathway. Golgi alterations have been observed in SMA, amyotrophic lateral sclerosis, Alzheimer’s disease, and other neurodegenerative disorders. Our data demonstrate that pathologically low levels of SMN alter the morphology and functionality of the Golgi apparatus. The overall premise of this proposal is that the COPI complex is necessary for processing and trafficking of cargoes essential for normal motor neuron maintenance. We have also shown that specific mRNAs are found in association with COPI. One class of cargo emphasized in this grant is mRNA selected for axonal transport. We propose genetic, biochemical, proteomic and transgenic approaches to define the properties and activities of the COPI complex and its interactions with SMN and other potential binding partners. We will create murine models to investigate the role of COPI in the neuron and perform correlative in vivo studies of axonogenesis, RNA trafficking and pathologic biological outcomes. Because SMN physically interacts with factors linked to other neurodegenerative diseases, thereby implicating commonality of causality, these experiments should result in new insights into the aberrant processes occurring in these disorders. Moreover, pharmacologic induction of the COPI pathway may represent a novel objective for treatment of SMA and other neurodegenerative diseases.
抽象的 脊柱肌肉萎缩(SMA)中运动神经元和肌肉功能障碍的发病机理,这是一种领先的遗传 婴儿死亡率的原因仍未解决。 SMA是由低水平的生存电动机神经元SMN产生的 蛋白质。这些实验的基本原理是我们发现SMN蛋白与并移动 在神经元与Copa蛋白一起,最大的是肝脏COPI夹具复合物的最大。 该建议的目的是确定降低SMN相互作用的分子机制 随着COPI复合物和COPI活动的丧失,会导致神经变性。 Golgi衍生的Copi蔬菜是 蛋白质的翻译后加工和运输所需的必要 设备和内质网和秘书途径。在SMA中观察到高尔基体改变 肌萎缩性侧索硬化症,阿尔茨海默氏病和其他神经退行性疾病。我们的数据 证明在病理上较低的SMN改变了高尔基的形态和功能 设备。该提案的总体前提是,COPI综合体对于处理和 对正常运动神经元维护必不可少的货物贩运货物。我们还表明了具体 与COPI联合发现mRNA。在这笔赠款中强调的一类货物是选择的mRNA 轴突运输。我们提出了遗传,生化,蛋白质组学和转基因方法来定义 COPI复合物的特性和活动及其与SMN和其他潜在结合的相互作用 合作伙伴。我们将创建鼠模型来研究COPI在神经元中的作用,并在 轴突生成,RNA运输和病理生物学结局的体内研究。因为SMN身体上 与与其他神经退行性疾病有关的因素相互作用 这些实验应导致对这些疾病中发生的异常过程的新见解。 此外,COPI途径的药物结肠诱导可能代表了治疗SMA的新目标 和其他神经退行性疾病。

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Interaction between alpha-COP and SMN ameliorates disease phenotype in a mouse model of spinal muscular atrophy.
α-COP 和 SMN 之间的相互作用可改善脊髓性肌萎缩小鼠模型的疾病表型。
Abnormal Golgi morphology and decreased COPI function in cells with low levels of SMN.
  • DOI:
    10.1016/j.brainres.2018.11.005
  • 发表时间:
    2019-03-01
  • 期刊:
  • 影响因子:
    2.9
  • 作者:
    Custer SK;Foster JN;Astroski JW;Androphy EJ
  • 通讯作者:
    Androphy EJ
Differential regulation of the SMN2 gene by individual HDAC proteins.
Mutations in the COPI coatomer subunit α-COP induce release of Aβ-42 and amyloid precursor protein intracellular domain and increase tau oligomerization and release.
  • DOI:
    10.1016/j.neurobiolaging.2021.01.003
  • 发表时间:
    2021-05
  • 期刊:
  • 影响因子:
    4.2
  • 作者:
    Astroski JW;Akporyoe LK;Androphy EJ;Custer SK
  • 通讯作者:
    Custer SK
Autophagy dysregulation in cell culture and animals models of spinal muscular atrophy.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ELLIOT J. ANDROPHY其他文献

ELLIOT J. ANDROPHY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ELLIOT J. ANDROPHY', 18)}}的其他基金

Small Molecule E6 Inhibitors to Treat Oropharyngeal Cancers Caused by HPV Infections
小分子 E6 抑制剂治疗 HPV 感染引起的口咽癌
  • 批准号:
    10484043
  • 财政年份:
    2022
  • 资助金额:
    $ 38.22万
  • 项目类别:
Small Molecule E6 Inhibitors to Treat Dysplasia Caused by HPV Infections
小分子 E6 抑制剂治疗 HPV 感染引起的发育异常
  • 批准号:
    10390563
  • 财政年份:
    2022
  • 资助金额:
    $ 38.22万
  • 项目类别:
Development of a mouse model to test HPV Antiviral compounds
开发小鼠模型来测试 HPV 抗病毒化合物
  • 批准号:
    10582890
  • 财政年份:
    2022
  • 资助金额:
    $ 38.22万
  • 项目类别:
Small-Molecule Covalent E6 Antagonists for Treatment of HPV Infection
小分子共价 E6 拮抗剂治疗 HPV 感染
  • 批准号:
    10220227
  • 财政年份:
    2021
  • 资助金额:
    $ 38.22万
  • 项目类别:
Small-Molecule Covalent E6 Antagonists for Treatment of HPV Infection
小分子共价 E6 拮抗剂治疗 HPV 感染
  • 批准号:
    10610388
  • 财政年份:
    2021
  • 资助金额:
    $ 38.22万
  • 项目类别:
Small-Molecule Covalent E6 Antagonists for Treatment of HPV Infection
小分子共价 E6 拮抗剂治疗 HPV 感染
  • 批准号:
    10397131
  • 财政年份:
    2021
  • 资助金额:
    $ 38.22万
  • 项目类别:
Optimization of a novel series of thiazolopyridines for the treatment of SMA
用于治疗 SMA 的新型噻唑并吡啶系列的优化
  • 批准号:
    8892548
  • 财政年份:
    2015
  • 资助金额:
    $ 38.22万
  • 项目类别:
Toward drug treatment of spinal muscular atrophy: Mechanism of action
脊髓性肌萎缩症的药物治疗:作用机制
  • 批准号:
    8823350
  • 财政年份:
    2014
  • 资助金额:
    $ 38.22万
  • 项目类别:
The COPA vesicle protein and pathogenesis of spinal muscular atrophy
COPA囊泡蛋白与脊髓性肌萎缩症发病机制
  • 批准号:
    8866202
  • 财政年份:
    2013
  • 资助金额:
    $ 38.22万
  • 项目类别:
The Indiana Cutaneous Biological Research Training Program
印第安纳州皮肤生物学研究培训计划
  • 批准号:
    8827676
  • 财政年份:
    2013
  • 资助金额:
    $ 38.22万
  • 项目类别:

相似海外基金

The mechanism of CELF1 upregulation and its role in the pathogenesis of Myotonic Dystrophy Type 1
CELF1上调机制及其在强直性肌营养不良1型发病机制中的作用
  • 批准号:
    10752274
  • 财政年份:
    2024
  • 资助金额:
    $ 38.22万
  • 项目类别:
Investigating the Formation and Function of Subgenomic Flavivirus RNAs During Flavivirus Infection of the Mosquito Vector
研究蚊子载体黄病毒感染过程中亚基因组黄病毒 RNA 的形成和功能
  • 批准号:
    10677398
  • 财政年份:
    2023
  • 资助金额:
    $ 38.22万
  • 项目类别:
Regulation of RNA sensing and viral restriction by RNA structures
RNA 结构对 RNA 传感和病毒限制的调节
  • 批准号:
    10667802
  • 财政年份:
    2023
  • 资助金额:
    $ 38.22万
  • 项目类别:
Understanding the full spectrum of epigenetic vulnerability in cancer through the delineation of DNA methylation function in gene 3' end
通过描绘基因 3 端 DNA 甲基化功能,全面了解癌症的表观遗传脆弱性
  • 批准号:
    10765365
  • 财政年份:
    2023
  • 资助金额:
    $ 38.22万
  • 项目类别:
Activity-Dependent Regulation of CaMKII and Synaptic Plasticity
CaMKII 和突触可塑性的活动依赖性调节
  • 批准号:
    10817516
  • 财政年份:
    2023
  • 资助金额:
    $ 38.22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了